Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 20/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 20/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 20/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 20/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 20/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 20/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 19/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 19/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 19/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823655 | 1.00 | HDAC4 (0.65) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823656 | 1.00 | HDAC4 (0.65) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823555 | 1.00 | HDAC4 (0.65) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823560 | 0.90 | HDAC3 (0.54) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823591 | 0.87 | HDAC3 (0.61) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823581 | 0.87 | HDAC3 (0.59) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823597 | 0.86 | HDAC3 (0.57) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823548 | 0.84 | ALOX5 (0.59) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823701 | 0.83 | HDAC1 (0.60) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823559 | 0.83 | HDAC1 (0.54) | HDAC4HDAC1HDAC7HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043174-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE COMPRISING SAME | BEIJING SUMMER SPROUT TECHNOLOGY CO., LTD (CN) | 2025-02-06 | — | — | US | claimed |
| US-12139501-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-11-12 | — | — | US | claimed |
| US-20240368465-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE COMPRISING SAME | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-11-07 | — | — | US | claimed |
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE LLC (US) | 2024-02-22 | — | — | US | claimed |
| US-11716900-B2 | Host materials for electroluminescent devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-01 | — | — | US | claimed |
| US-11711969-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-25 | — | — | US | claimed |
| US-20230006153-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-01-05 | — | — | US | claimed |
| WO-2022224118-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE, LLC (US) | 2022-10-27 | — | — | WO | claimed |
| EP-4029501-A1 | COMBINATION OF POLYAROMATIC UREA DERIVATIVES AND GLUCOCORTICOID OR HDAC INHIBITOR FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH MUSCLE CELLS AND/OR SATELLITE CELLS | Anagenesis Biotechnologies (FR) | 2022-07-20 | — | — | EP | claimed |
| US-11374181-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2022-06-28 | — | — | US | claimed |
| US-20250313585-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250109206-A1 | ACTIVATABLE BISPECIFIC ANTI-CD3 AND ANTI-PD-L1 PROTEINS AND USES THEREOF | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-04-03 | — | — | US | disclosed |
| CN-119677780-A | Activatable bispecific anti-CD 3 and anti-PD-L1 proteins and uses thereof | 森特萨制药(英国)有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4499232-A1 | ACTIVATABLE BISPECIFIC ANTI-CD3 AND ANTI-PD-L1 PROTEINS AND USES THEREOF | Centessa Pharmaceuticals (UK) Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| WO-2010014220-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11711969-B2 | Organic electroluminescent materials and devices | RPS4X, NCOA4, KCNN4 | HDAC4 200/4885HDAC1 781/4885HDAC7 2107/4885 |
| US-20250313585-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | L1CAM, AP2M1, LAGE3 | HDAC4 2864/4885HDAC1 1312/4885HDAC7 3924/4885 |
| US-12139501-B2 | Organic electroluminescent materials and devices | L1CAM, LEF1, EPCAM | HDAC4 4440/4885HDAC1 2450/4885HDAC7 4472/4885 |
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | BAG3, BAG2, PHB1 | HDAC4 1671/4885HDAC1 2195/4885HDAC7 2334/4885 |
| US-20230006153-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, OTC | HDAC4 3287/4885HDAC1 3518/4885HDAC7 3984/4885 |
| US-20090143445-A1 | HDAC Inhibitors | HDAC3, HDAC7, HDAC4 | HDAC4 3/4885HDAC1 6/4885HDAC7 2/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | HDAC4 4133/4885HDAC1 3361/4885HDAC7 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.